Form 4 for DGX Quest Diagnostics
Accepted 2025-11-20 00:00:00 ET · period of report 2025-11-18 · accession 0001955265-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-20 | 2025-11-18 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | M - OptEx | $144.46 | +7,946 | 15.5K | +106% | +$1.15M |
| D | 2025-11-20 | 2025-11-18 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | S - Sale+OE | $187.35 | -7,946 | 7,530 | -51% | -$1.49M |
| DM | 2025-11-20 | 2025-11-18 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | M - OptEx | $144.46 | -7,946 | 7,484 | -51% | -$1.15M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-18 | M | A | 7,846 | $144.47 | 15,376 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-18 | S | D | 7,946 | $187.35 | 7,530 | D | — | — | |
| 3 | Common | Common Stock | 2025-11-18 | M | A | 100 | $143.33 | 15,476 | D | — | — | |
| 4 | Derivative | Non-Qualifed Stock Option (right to buy) | 2025-11-18 | M | D | 7,846 | $144.47 | 0 | D | $144.47 · — to 2032-03-21 | 7,846 Common Stock | (F2) The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. |
| 5 | Derivative | Non-Qualifed Stock Option (right to buy) | 2025-11-18 | M | D | 100 | $143.33 | 7,484 | D | $143.33 · — to 2033-02-23 | 100 Common Stock | (F2) The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. |